If you have been reading about batch purity and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-07-16. Numbers and descriptions here follow the published literature rather than marketing material.
Development took place at the Institute of Molecular Genetics of the Russian Academy of Sciences, where a series of short peptides were designed in the 1980s and 1990s. Selank was selected from variants of tuftsin that showed resistance to plasma peptidases. Russian regulatory approval covers it as an anxiolytic agent given intranasally. Outside that market the compound is normally handled as a research chemical rather than a medicine, and no widely recognised international pharmacopoeial monograph exists. The name Selank is a coined trade designation rather than a systematic chemical name.
Enzymatic stability motivates the extra three residues at the carboxyl end. Native tuftsin is cleaved quickly by circulating aminopeptidases and carboxypeptidases, which limits its duration of action and its usefulness as a tool compound. Extending the chain with proline-rich segments is a common design tactic because proline constrains the backbone and slows proteolysis. The same Pro-Gly-Pro motif appears in other Russian-developed peptides of the era. Whether the full seven-residue chain is required for activity, or whether it acts mainly as a prodrug releasing tuftsin, remains unresolved.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography, with mass spectrometry used to confirm molecular mass and sequence information. Amino acid analysis and peptide mapping may supplement these methods. Certified reference standards are scarce, and many commercial lots are sold as research chemicals without a pharmacopoeial monograph. Regulatory treatment differs by country: Selank is a registered prescription medicine in Russia, while in the European Union and the United States it is not an approved drug and may fall under research-chemical or unapproved-product frameworks.
Selank is a hydrophilic peptide and dissolves readily in water and in aqueous buffers. The lyophilised powder is typically a white to off-white solid. Because short peptides are prone to hydrolysis and oxidation, handling benefits from limiting exposure to heat, moisture and strong light. Working solutions are commonly prepared in sterile water or saline, and repeated freeze-thaw cycles are avoided to reduce aggregation and loss of activity. These practices reflect general laboratory convention rather than published stability specifications.
Dry powder is normally held at -20 degrees Celsius or lower, in a sealed container with desiccant and protection from light. Reconstituted solutions are usually kept at 2 to 8 degrees Celsius for short periods and frozen for longer ones. Proline residues at several positions are generally associated with some resistance to peptidase attack, but chemical stability still declines at neutral to alkaline pH and at elevated temperature. Exact shelf-life figures are product-specific and are not standardised across suppliers.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic heptapeptide | Tuftsin analogue with a C-terminal Pro-Gly-Pro tail |
| Amino acid sequence | Thr-Lys-Pro-Arg-Pro-Gly-Pro | Abbreviated TKPRPGP in most catalogues |
| Molecular mass | About 752 Da | Value for the free peptide |
| Solubility | Freely soluble in water | Aqueous solutions are kept cold and used promptly |
| Typical storage | -20 °C, dry, protected from light | Applies to the lyophilised powder before reconstitution |
Published clinical evidence is limited. Most controlled trials were conducted in Russia, enrolled modest numbers of participants, and appeared in Russian-language journals, which restricts independent verification. Reported outcomes include lower anxiety scores, improved attention and memory measures, and changes in fatigue ratings. Reviews written in English note methodological limitations such as small samples and inconsistent endpoints. Whether the compound produces clinically meaningful benefit relative to established anxiolytics is therefore an open question rather than an established finding.
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. It was designed at the Institute of Molecular Genetics of the Russian Academy of Sciences as a structural analogue of tuftsin, a naturally occurring tetrapeptide fragment of the immunoglobulin heavy chain. The added Pro-Gly-Pro tail was intended to slow enzymatic degradation and extend biological activity. In Russia it is registered as an anxiolytic nasal preparation, while regulators elsewhere have not approved it for clinical use.
Reverse-phase high-performance liquid chromatography with ultraviolet detection near 214 nanometres is the standard purity method. Mass spectrometry, typically electrospray ionisation, confirms identity through the expected mass-to-charge pattern. Amino acid analysis can verify composition independently. Chiral purity requires separate techniques such as derivatisation followed by chromatographic separation, and such data are rarely reported for research-grade material.
Quantification in biological matrices relies on liquid chromatography coupled to tandem mass spectrometry with stable-isotope internal standards. Low plasma concentrations and adsorption to container surfaces both complicate measurement. Solid-phase extraction is often needed to reduce matrix interference before injection. Reported limits of quantification differ widely between laboratories, which makes direct comparison of pharmacokinetic results difficult and limits meta-analysis.
Peptide bonds are vulnerable to protease attack, and Selank is no exception. Measured half-life in serum is short, on the order of minutes in several reports, which explains why intranasal administration is the common route described in the literature. Absorption across the nasal mucosa partially bypasses first-pass hepatic metabolism. Quantitative data on human bioavailability remain limited and are difficult to compare across studies.
Additionally, patients have not substituted other drugs as a method of overdose. The decision to withdraw co-proxamol has met with some controversy; it has been brought up in the House of Commons on two occasions, 13 July 2005 and on 17 January 2007. Patients have found alternatives to co-proxamol either too strong, too weak, or with intolerable side effects. During the House of Commons debates, it is quoted that originally some 1,700,000 patients in the UK were prescribed co-proxamol. Following the phased withdrawal, this has eventually been reduced to 70,000. However, this apparently is the residual pool of patients who cannot find alternate analgesia to co-proxamol. The safety net of prescribing co-proxamol after license withdrawal from 31 December 2007, on a "named patient" basis where doctors agree a clinical need exists, has been rejected by most UK doctors because the wording that "responsibility will fall on the prescriber" is unacceptable to most doctors. Some patients intend to take the case to the European Court of Human Rights. However, the European Medicines Agency has recently backed the agency's decision, and recommended in June 2009 that propoxyphene preparations be withdrawn across the European Union. On 28 March 2017, NHS Clinical Commissioners announced that co-proxamol will be no longer available under NHS England as part of £400m of spending cuts for prescriptions that are believed to have little or no clinical value.
Following the first presidential debate of the general election, in which Obama's performance was considered surprisingly lackluster, his lead over Romney collapsed, putting pressure on Biden to stop the bleeding with a strong showing against the Republican vice-presidential nominee, Paul Ryan. Some political analysts considered Biden's performance in the October 11 vice-presidential debate one of the best of his career and a key factor in Obama's rebound in the polls and eventual victory. The debate also became memorable for the popularization of Biden's use of the phrase "a bunch of malarkey" in response to an attack by Ryan on the administration's response to the attacks on the U.S. embassy in Benghazi in September. Biden reused the phrase during his 2020 presidential campaign. On November 6, Obama and Biden were reelected.
Obesity in children is treated with dietary changes and physical activity, often through an intensive counselling and lifestyle changes program. At least sixty minutes of daily moderate to high intensity aerobic physical activity is recommended for all children (regardless of BMI). Dieting, including caloric restriction or very low calorie diets, and missing meals should however be discouraged, as it is associated with psychological harm, risks of dietary or nutritional deficiencies and a risk of developing eating disorders later in life. The benefit of tracking BMI and providing counselling around weight is minimal. Brief primary care weight management interventions (e.g. delivered by a physician or nurse practitioner) have only a marginal positive effect in reducing childhood overweight or obesity.
== Relevance to human disease == Neuropeptides such as relaxin-3 are attracting increasing interest as targets for the pharmacological treatment of a range of neuropsychiatric diseases. Due to the ability of relaxin-3 to modulate neuronal processes/behaviours such as mood, stress responses and cognition, which are often aberrant in mental illnesses, considerable potential exists for the development of relaxin-3-based drugs to therapeutically treat depression and other mental illnesses.
The Altıkulaç Sarcophagus, or Çan sarcophagus, is an early 4th century BCE (400–375 BCE) sarcophagus. It is sometimes said to be in the Greco-Persian style. The sarcophagus was found in 1998 in a circular corbel-vaulted tomb within the Çingenetepe tumulus, in the village of Altıkulaç, near Çan, in the eastern Troad, about halfway between Troy and Daskyleion, in what was anciently Hellespontine Phrygia. It was looted and damaged in the process, but a large part of the reliefs remained intact. It is made of painted marble carved in low relief, and dated to the 1st quarter 4th century BCE. It was made at about the same time as the famous tombs in Lycia. The sarcophagus can probably be attributed to an Anatolian dynast of Hellespontine Phrygia. The longer face of the sarcophagus is decorated with two hunting scenes, the hunting of a fallow buck on the left portion, and the hunting of a boar on the right portion. The shorter face of the sarcophagus is decorated with a battle scene, with a mounted, armoured warrior, accompanied by his henchman, spearing a fallen light-armed soldier, probably a Greek psilos. The rider was almost certainly the dynast to whom the sarcophagus belonged. His henchman, judging from his appearance, was probably a Greek mercenary in the service of the cavalryman, a common occurrence at the time. The other two sides are undecorated. The sarcophagus nevertheless derives from a long tradition of royal iconography in the Near East, especially visible in the tombs of Asia Minor.
Sources: en.wikipedia.org
In adults, the primary metabolic pathway for paracetamol is glucuronidation. This yields a relatively non-toxic metabolite, which is excreted into bile and passed out of the body. A small amount of the drug is metabolized via the cytochrome P-450 pathway (to be specific, CYP3A4 and CYP2E1) into NAPQI, which is extremely toxic to liver tissue, as well as being a strong biochemical oxidizer. In an average adult, only a small amount (approximately 10% of a therapeutic paracetamol dose) of NAPQI is produced, which is inactivated by conjugation with glutathione (GSH). The amount of NAPQI produced differs in certain populations. The minimum dosage at which paracetamol causes toxicity usually is 7.5 to 10g in the average person. The lethal dose is usually between 10 g and 15 g. Concurrent alcohol intake lowers these thresholds significantly. Chronic alcoholics may be more susceptible to adverse effects due to reduced glutathione levels. Other populations may experience effects at lower or higher dosages depending on differences in P-450 enzyme activity and other factors which affect the amount of NAPQI produced. In general, however, the primary concern is accidental or intentional paracetamol overdose. When a toxic dose of paracetamol is ingested, the normal glucuronide pathway is saturated and large amounts of NAPQI are produced. Liver reserves of glutathione are depleted by conjugation with this excess NAPQI.
==== MeSH E05.393.661 – nucleic acid hybridization ==== MeSH E05.393.661.124 – branched dna signal amplification assay MeSH E05.393.661.250 – heteroduplex analysis MeSH E05.393.661.475 – in situ hybridization MeSH E05.393.661.475.350 – in situ hybridization, fluorescence MeSH E05.393.661.475.350.125 – chromosome painting MeSH E05.393.661.475.680 – primed in situ labeling MeSH E05.393.661.640 – oligonucleotide array sequence analysis
Liberation – the process of active pharmaceutical ingredients (API) separating from its pharmaceutical formulation. See also IVIVC. Absorption – the process of a drug entering into systemic circulation from the site of administration. Distribution – the dispersion or dissemination of substances throughout the fluids and tissues of the body. Metabolism (or biotransformation, or inactivation) – the chemical reactions of the drug and irreversible breakdown into metabolites (e.g. by metabolic enzymes such as cytochrome P450 or glucuronosyltransferase enzymes). Excretion – the removal of the substance or metabolites from the body. In rare cases, some drugs irreversibly accumulate in body tissue. Some textbooks combine the first two phases as the drug is often administered in an active form, which means that there is no liberation phase. Others include a phase that combines distribution, metabolism and excretion into a disposition phase. Other authors include the drug's toxicological aspect in what is known as ADME-Tox or ADMET. The two phases of metabolism and excretion can be grouped together under the title elimination. The study of these distinct phases involves the use and manipulation of basic concepts in order to understand the process dynamics.
== Pharmaceuticals == The vaccine vial monitors are a family of TTIs used by the World Health Organization to track the degradation of vaccines. This is important as many places in the world do not have a reliable cold chain and vaccines tend to spend some time not refrigerated. Based on data on how long a vaccine stays useful at different temperatures, a VVM that matches the vaccine's degradation behavior is chosen. The VVM takes into account all heat exposures except for small peaks. TTIs are also used to protect other heat-sensitive drugs, many of which are complex biologics. Vaccines are a kind of biologics.
== Other use of sake kasu == Sake kasu can be found in different cosmetics and skincare products such as facial masks, bath powder, and face cream. There is an old folktale about an elderly man who worked in a brewery with youthful-looking hands compare to his old wrinkled face; in light of this, different cosmetics companies use sake kasu as an ingredient and a selling point for their product. A research scientist found an old sake brewer who had no wrinkles on his hands due to the constant contact with the yeast produced during the sake fermentation process. Other research focused on the yeast produced during the sake fermentation process leading to a product line called Pitera. Sake kasu can also be used as the main ingredient for homemade beauty products including sake kasu facial masks and body masks. Adding citrus fruit juice, honey, and rice water, aloe vera or rose water to sake kasu can create a mask for both face and body. It brightens the users' skin and the antioxidants in the mask can stimulate collagen production. Because sake kasu contains alcohol, it is recommended that sunscreen be applied before using the homemade sake kasu mask. Sake kasu can be beneficial for cosmetic use due to the high amount of triacylglycerols found in freeze-dried sake kazu. Tyrosinase catalytic activity is hindered by the n-hexane extract from freeze-dried sake kasu. Tyrosinase inhibitor was further purified by the n-hexane extract from the freeze-dried sake kasu.
Sources: en.wikipedia.org
Selank is a seven-amino-acid peptide built from the tuftsin sequence plus a Pro-Gly-Pro tail. It is produced by chemical synthesis rather than extracted from a natural source. The free peptide is usually supplied as a lyophilised powder or in an aqueous formulation.
Tuftsin is a natural tetrapeptide derived from the Fc portion of immunoglobulin G. Selank retains that tetrapeptide at its N-terminus and adds three residues to improve resistance to enzymatic breakdown. The relationship is structural, and the two molecules are not interchangeable in experimental work.
It holds a product registration in Russia for intranasal use as an anxiolytic. Registrations of that kind are not automatically accepted by regulators elsewhere. In most other countries it is treated as an unapproved substance or a research material.
Dry powder is normally held at -20 degrees Celsius or below in a sealed, light-protected container with desiccant. Brief room-temperature handling during weighing is generally tolerated. Storage instructions vary between suppliers, so the accompanying certificate of analysis should be followed.